AbbVie's 20% YoY increase in R&D spending to $2.47B is a strategic move to strengthen its entire drug pipeline and mitigate revenue loss from drugs like Humira.
Filing excerpt
Research and development (R&D) expenses as a percentage of net revenues increased for the three months ended March 31, 2026 compared to the prior year primarily due to increased funding to support all stages of the company’s pipeline assets.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-10qplatformStrategyGet every 10-Q signal for AbbVie and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/5cdc414e-aa8b-4181-b7fa-9c3af83b456d returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.
{
"signal_id": "5cdc414e-aa8b-4181-b7fa-9c3af83b456d",
"signal_type": "sec-10q",
"signal_subtype": "platformStrategy",
"detected_at": "2026-05-12T09:24:56.954+00:00",
"company": {
"name": "AbbVie",
"domain": "abbvie.com"
},
"data": {
"detail": "AbbVie's 20% YoY increase in R&D spending to $2.47B is a strategic move to strengthen its entire drug pipeline and mitigate revenue loss from drugs like Humira. This significant budget increase creates immediate opportunities for vendors in clinical trial management, R&D data platforms, lab automation, and scientific collaboration tools.",
"metrics": {
"pct": 0.2,
"timeframe": "current_quarter",
"pct_context": "Year-over-year increase in R&D expense",
"dollar_context": "Research and development expense for the three months ended March 31, 2026",
"dollar_millions": 2472
},
"summary": "AbbVie boosts R&D spending by 20% to $2.47B to fund entire drug pipeline",
"excerpts": "Research and development (R&D) expenses as a percentage of net revenues increased for the three months ended March 31, 2026 compared to the prior year primarily due to increased funding to support all stages of the company’s pipeline assets.",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/abbv-20260331.htm",
"filing_date": "2026-05-08",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "03/31",
"sales_relevance": "Platform tools needed",
"signal_category": "strategic"
}
}
curl https://signals.autobound.ai/v1/signals/5cdc414e-aa8b-4181-b7fa-9c3af83b456d \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.